Join Growin Stock Community!

豐技生技6744.TW Overview

TW StockBiotech. & Medical
(No presentation for 6744)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

豐技生技（6744）Overall Performance

豐技生技（6744）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

豐技生技（6744） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

豐技生技（6744）Key Information

豐技生技（6744）Profile

Feng Chi Biotech Corp. provides preimplantation genetic testing, prenatal testing, life science, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company is based in Taipei, Taiwan.

豐技生技（6744）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.50
PE Ratio (TTM)
6.81
Forward PE
-
PS Ratio (TTM)
0.73
PB Ratio
1.12
Price-to-FCF
3.40
METRIC
VALUE
vs. INDUSTRY
Gross Margin
44.45%
Net Margin
10.66%
Revenue Growth (YoY)
-4.13%
Profit Growth (YoY)
-5.48%
3-Year Revenue Growth
8.46%
3-Year Profit Growth
7.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.50
PE Ratio (TTM)
6.81
Forward PE
-
PS Ratio (TTM)
0.73
PB Ratio
1.12
Price-to-FCF
3.40
Gross Margin
44.45%
Net Margin
10.66%
Revenue Growth (YoY)
-4.13%
Profit Growth (YoY)
-5.48%
3-Year Revenue Growth
8.46%
3-Year Profit Growth
7.76%
default symbol

6744

豐技生技

17.00D

-2.94%

(-0.03)

  • When is 6744's latest earnings report released?

    The most recent financial report for 豐技生技 (6744) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6744's short-term business performance and financial health. For the latest updates on 6744's earnings releases, visit this page regularly.

  • Where does 6744 fall in the P/E River chart?

    According to historical valuation range analysis, 豐技生技 (6744)'s current price-to-earnings (P/E) ratio is 17.32, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 6744 have?

    At the end of the period, 豐技生技 (6744) held Total Cash and Cash Equivalents of 13.23M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6744 go with three margins increasing?

    In the latest report, 豐技生技 (6744) achieved the “three margins increasing” benchmark, with a gross margin of 45.71%%, operating margin of 10.57%%, and net margin of 9.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6744's profit trajectory and future growth potential.